Zanamivir
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Zanamivir: From Influenza to Pyelonephritis
One-Sentence Summary
Zanamivir is a neuraminidase inhibitor originally used to treat influenza. The TxGNN model predicts it may be effective for pyelonephritis, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Influenza (the approved indication text on the Singapore licence is blank; the original indication comes from the knowledge graph) |
| Predicted New Indication | Pyelonephritis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, zanamivir is a viral neuraminidase inhibitor. Its efficacy in influenza is established, but this mechanism does not obviously apply to pyelonephritis.
Pyelonephritis is typically a bacterial infection of the kidney, and zanamivir has no known antibacterial activity. No plausible mechanistic link between the original and the predicted indication is evident. The high score (0.998) is a computational output only. It may reflect an infection-related association in the knowledge graph rather than a therapeutic rationale.
Other predictions in the top 10 (tyrosine and phenylalanine metabolism disorders, Pierre Robin syndrome, Legionnaire disease, HIV, dengue, aspergillosis, and schistosomiasis susceptibility) also lack mechanistic support. The few publications retrieved for them concern influenza neuraminidase resistance, not those diseases.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for pyelonephritis.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11199P | RELENZA ROTADISK 5 mg/dose | Powder, metered | Not stated in the registration data |
Safety Considerations
- Contraindications (knowledge-graph associations, not label text): epilepsy, chronic obstructive pulmonary disease, severe early-onset COPD, bronchial disease, delirium.
- Drug Interactions: 8 interactions were found. One is rated Moderate: inhaled rapid-acting human insulin. The following are of unknown severity: clarithromycin, loratadine, montelukast, ketotifen, fexofenadine, ibuprofen, and diclofenac.
Please refer to the package insert for further safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature and no plausible mechanism, since zanamivir targets viral neuraminidase and pyelonephritis is bacterial. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Mechanism of action data and a credible biological rationale for pyelonephritis
- Preclinical or clinical evidence supporting this indication
- Package insert warnings and contraindications, so safety screening can begin
- Assessment of whether the inhaled powder formulation can reach the target tissue (route compatibility)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.